PONES

Actelion is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative treatments for orphan diseases, with a primary focus on pulmonary arterial hypertension (PAH). The company is best known for its pioneering work in endothelin receptor antagonists and sphingosine-1-phosphate (S1P) receptor modulators. Its portfolio includes blockbuster treatments such as Tracleer, Opsumit, and Uptravi, as well as the S1P1 receptor modulator ponesimod (Ponvory) for multiple sclerosis. Following its acquisition by Johnson & Johnson in 2017, Actelion's operations were integrated into the Janssen Pharmaceutical Companies, where it continues to drive advancements in pulmonary vascular and specialty medicine.